08/09/22 4:05 PMNasdaq : STSA earningslow floatSatsuma Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Progress in STS101 Development Program- Completed enrollment in the SUMMIT pivotal Phase 3 efficacy trial of STS101, randomizing more than 1,400 subjects - - On track to announce SUMMIT trial topline results in Q4 2022 - - Completed STS101 clinical and CMC pre-NDA meetings with FDA - - Presented nine abstracts at major medical meetingsRHEA-AIneutral
08/02/22 8:00 AMNasdaq : STSA clinical triallow floatSatsuma Pharmaceuticals Announces Completion of Enrollment in SUMMIT Pivotal Phase 3 Efficacy Trial of STS101 for the Acute Treatment of MigraineSatsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101RHEA-AIneutral
06/09/22 7:00 AMNasdaq : STSA low floatSatsuma Pharmaceuticals Announces Five Abstracts Accepted for Presentation at The American Headache Society’s 64th Annual Scientific MeetingSatsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamineRHEA-AIneutral
06/07/22 4:05 PMNasdaq : STSA low floatSatsuma Pharmaceuticals Hosting Key Opinion Leader Webinar on the Acute Treatment of Migraine, DHE, and STS101Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic productRHEA-AIneutral
05/11/22 4:05 PMNasdaq : STSA conferenceslow floatSatsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment ConferenceSatsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment ofRHEA-AIneutral
05/10/22 4:05 PMNasdaq : STSA earningslow floatSatsuma Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing and on track to read out topline results in Q4 2022 - - New Drug Application (NDA) submission anticipated in Q1 2023 - - $80.6 million in cash, cash equivalents and marketable securities as of March 31, 2022, provides runway into second halfRHEA-AIneutral
03/15/22 4:03 PMNasdaq : STSA earningslow floatSatsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business Highlights- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing; key trial on track to read out topline results in Q4 2022 - - $95.8 million in cash, cash equivalents and marketable securities as of December 31, 2021, provides runway into second half of 2023 - SOUTH SAN FRANCISCO, Calif., March 15, 2022RHEA-AIpositive
03/03/22 4:05 PMNasdaq : STSA low floatSatsuma Pharmaceuticals Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2022 Annual MeetingSatsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment ofRHEA-AIneutral
02/08/22 8:30 AMNasdaq : STSA conferenceslow floatSatsuma Pharmaceuticals to Present at the Virtual 11th Annual SVB Leerink Global Healthcare ConferenceSatsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment ofRHEA-AIneutral
11/09/21 4:05 PMNasdaq : STSA earningslow floatSatsuma Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing, with topline results expected second half of 2022 - - Appointed Mutya Harsch to the Board of Directors – - $110 million in cash as of September 30, 2021 provides runway into second half of 2023 – SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021RHEA-AIvery positive